Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Subscribe To Our Newsletter & Stay Updated